Clik here to view.
MaRS Innovation establishes co-managed fund with Johnson & Johnson
MaRS Innovation (MI) has signed a co-funding agreement with the Johnson & Johnson Corporate Office of Science and Technology to capitalize and accelerate the use of Toronto-based life sciences...
View ArticleClik here to view.
York University becomes 17th Member of MaRS Innovation
MaRS Innovation to act as commercialization agent for York’s life sciences and technology discoveries, leveraging new potential for York’s existing $70 million in research initiatives TORONTO, May 9,...
View ArticleClik here to view.
MaRS Innovation and GlaxoSmithKline Announce Strategic Partnership to...
TORONTO (May 31, 2011) — MaRS Innovation (MI) and GlaxoSmithKline Inc. (GSK) today announced a new development fund — the GSK-MaRS Innovation Fund — that will support and fast-track the...
View ArticleClik here to view.
Business Without Borders highlights ScarX Therapeutics’ Chinese...
ScarX Therapeutics, a spin-off company created by MaRS Innovation and The Hospital for Sick Children (SickKids), was profiled by Business Without Borders on September 25, 2012. Sean Fine‘s article...
View ArticleClik here to view.
Xconomy names Xagenic to 2012′s Biotech Startup Class
MI spin-off company one of 30 listed in North America and the United Kingdom Xconomy, a U.S.-based business news website, named Xagenic to its 2012 Biotech Startup Class. Luke Timmerman‘s article,...
View ArticleClik here to view.
OCE invests $250,000 in ScarX Therapeutics’ revolutionary anti-scarring...
TORONTO, ON (Jan. 24, 2013) – ScarX Therapeutics, a start-up company commercializing a groundbreaking treatment to dramatically reduce post-operation scarring, is receiving a $250,000 investment from...
View ArticleClik here to view.
What does MaRS Innovation’s funding extension mean for Toronto’s academic...
Every six weeks, MaRS Innovation’s marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI’s activities or one of our start-up companies. You can read...
View ArticleMerck invests in pan-Canadian life sciences research innovation sector
A $4-million public-private partnership will promote research innovation involving three academic commercialization centres in Canada CHICAGO, Illinois – April 22, 2013 – Merck Canada will be...
View ArticleClik here to view.
Canadian biotech sector makes strong showing at BIO2013
Every six weeks, MaRS Innovation’s marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI’s activities or one of our start-up companies. You can read...
View ArticleClik here to view.
Dr. Raphael Hofstein in Biotechnology Focus: Building a catalytic reaction...
Dr. Raphael Hofstein, president & CEO, MaRS Innovation. Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by MaRS Innovation President &...
View ArticleClik here to view.
Bringing mad science to mass production: Financial Post features the Bio...
University of Toronto PhD student Lian Len with a prototype tissue printer. Photo courtesy of Dominic Ali (University of Toronto) “It’s one thing to invent a machine that prints skin, but it’s a whole...
View ArticleClik here to view.
Cellax profiled in SciBX; MaRS Innovation’s MSc PoP program cited in National...
The Cellax technology was profiled in a recent issue of SciBX (subscription necessary). MaRS Innovation is mentioned in the article as the technology’s commercialization agent. Here’s an excerpt:...
View ArticleClik here to view.
WaveCheck’s Crowdfunding Campaign Featured on CTV National News and Canada AM
Indiegogo campaign raised $53,390 from over 500 worldwide donors WaveCheck co-inventor, Dr. Gregory Czarnota, appeared on CTV National News on December 15. CTV National News featured WaveCheck’s...
View ArticleClik here to view.
MaRS Innovation Statement on 2014 Ontario Budget
TORONTO, ON (May 2, 2014) – MaRS Innovation congratulates the government’s deepened commitment to support the life sciences through research and innovation funding. In particular, the new $30 million...
View ArticleClik here to view.
Dr. Rafi Hofstein in Biotechnology Focus: What will it take to regain...
Dr. Raphael Hofstein, president & CEO, MaRS Innovation. Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by MaRS Innovation President &...
View ArticleClik here to view.
Triphase Accelerator announces new cancer collaboration with Sunnybrook...
TORONTO and SAN DIEGO (Feb. 26, 2015) — Triphase Accelerator Corporation has entered into an academic center collaboration with Sunnybrook Research Institute (SRI), the research arm of Sunnybrook...
View ArticleClik here to view.
Global University Venturing features MaRS Innovation’s unique model for...
Dr. Raphael Hofstein, president & CEO, MaRS Innovation. MaRS Innovation’s “model solves the two weakest points in tech transfer: the lack of dealflow and the ability to match public funding,”...
View Article
